RaySearch Laboratories AB ( ($SE:RAY.B) ) has issued an announcement.
In the first quarter of 2025, RaySearch Laboratories AB reported a 29% increase in net sales, driven by a significant rise in license and support revenues. The company achieved an operating profit of SEK 74.8 million, with notable orders including a major contract with Heyou Hospital in China. The release of RayStation v2025 and its adoption by The Royal Marsden NHS Foundation Trust highlights RaySearch’s ongoing innovation and strong market positioning, potentially enhancing its influence in the radiation therapy sector.
More about RaySearch Laboratories AB
RaySearch Laboratories AB operates in the medical technology industry, focusing on advanced software solutions for radiation therapy in cancer treatment. The company’s primary product, RayStation, is a treatment planning system used by over 1,100 clinics worldwide, and it continues to expand its market presence with significant orders from international clients.
Average Trading Volume: 179,721
Current Market Cap: SEK8.76B
Find detailed analytics on RAY.B stock on TipRanks’ Stock Analysis page.